In this episode of Compound Wisdom, we sit down with Dr. James Lavelle, a clinical pharmacist, board-certified clinical nutritionist, bestselling author of Cracking the Metabolic Code, and a leading authority on peptides and metabolic health.

We explore why the traditional medical system often misses root causes, how peptides and GLP-1 therapies should be used responsibly, and why bloodwork, lifestyle, and hormone balance are essential for longevity and performance.

• Why aging doesn’t have to mean physical decline
• How peptides actually work and why sourcing matters
• The difference between research-only peptides and human-use peptides
• The right way to approach GLP-1s for weight loss and metabolic health
• What causes “Ozempic face” and how to avoid it
• How The Metabolic Code identifies your biggest metabolic roadblocks
• When bloodwork, HRT, and TRT make sense for men and women

Dr. James Lavelle is a clinical pharmacist, board-certified clinical nutritionist, bestselling author, and founder of The Metabolic Code. With over 40 years in healthcare, he is widely recognized as a pioneer in integrative, regenerative, and peptide-based medicine.

• Cracking the Metabolic Code — Dr. James Lavelle
• The Metabolic Code framework
• Peptides discussed: BPC-157, Sermorelin, KPV, GHK-Cu
• GLP-1 medications: Ozempic, Mounjaro

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting peptides, GLP-1 medications, hormone therapy, or any medical treatment.

Episode Summary

Can AI really replace doctors, or is it simply changing how medicine is delivered?

In this episode of Compound Wisdom, Dr. Sean Arora shares a blunt, experience-driven perspective on AI in healthcare, why he left traditional hospital medicine after COVID, and how physician-led telehealth and preventative care are shaping the future of modern medicine.

Guest

Dr. Sean Arora — Physician licensed in all 50 U.S. states, Founder of Arora Health Group, specializing in telehealth, preventative medicine, HRT, peptides, and regenerative health.

Key Topics Covered

• Can AI replace doctors, or only assist them?
• Why traditional healthcare fails at prevention
• Leaving hospital medicine after COVID
• Telehealth done right vs. dangerous shortcuts
• HRT for men vs. women and why customization matters
• Peptides, GLP-1s, and Ozempic: hype vs. reality
• The risks of social-media medical advice
• Why lab work is the foundation of longevity care
• Ethical and regulatory risks in modern telehealth

Resources Mentioned

• Telehealth & preventative medicine platforms
• Hormone Replacement Therapy (HRT)
• Peptides & regenerative therapies
• GLP-1 medications (Ozempic, Mounjaro)
• Wearable health data (Oura, Whoop)

Disclaimer

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medical treatment.

“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge

In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.

Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.

The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.

1. Friction in healthcare kills trust, outcomes, and conversion
2. 
   
3. Great medicine often fails because of broken delivery systems
4. 
   
5. Education-first models outperform traditional clinic selling
6. 
   
7. Stem cells can be explained without medical jargon
8. 
   
9. You don’t need to leave the U.S. for legitimate stem cell access
10. 
    
11. FDA “non-approval” does not mean illegal or ineffective
12. 
    
13. Cultured and expanded cells overseas carry unknown risks
14. 
    
15. IV stem cells and exosomes are emerging wellness tools
16. 
    
17. Concierge, mobile care improves patient experience and scale
18. 
    
19. Regulation can eliminate bad actors and reward compliant operators
20. 
    

00:01 Friction Kills Conversion

02:07 Seth’s Entry Into Stem Cells Through Sales

04:13 Full Rooms, Zero Conversions

05:42 Removing Friction From the Model

06:22 Why Dinner Seminars Still Work

09:12 Stem Cells Explained Simply

11:14 The Overseas Stem Cell Myth

13:47 Cultured Cells vs Non-Manipulated Tissue

15:42 Marketing Limits in the U.S.

17:01 IV Stem Cells and Exosomes

19:31 How Often to Use Stem Cells for Optimization

20:24 Pricing, Access, and Market...

“Doctors don’t have the training or the tools to help what she’s going through.” – Matthew Stern

In this episode of Compound Wisdom, Steve Sood sits down with Matthew Stern, founder of MyStart Health, to break down what’s actually changing inside telehealth—and why GLP-1s are only the beginning.

Matthew shares how he spent 20 years building businesses through digital marketing and full-funnel “customer journey” systems, then applied that same growth discipline to healthcare. He explains how MyStart scaled to 13,000 patients, why the business unexpectedly became 85% women (mostly 50+), and what he learned once he got deeper into the realities of doctors, pharmacies, and personalized medication protocols.

The conversation turns personal as Matthew describes his mom’s menopause experience, his wife’s postpartum hormone journey, and the recurring pattern many patients face: “your labs look great” while they still don’t feel right. From HRT and women’s hormone care to microdosing GLP-1s, blood work-driven longevity, and the “Wild West” of research peptides, this episode maps where modern healthcare is failing—and where telehealth is quietly heading next.

Takeaways

Access and affordability are the real bottlenecks in healthcare

MyStart scaled to 13,000 patients after launching last August

GLP-1s are expanding beyond weight loss into broader health use cases

Most of MyStart’s patients are women over 50 (about 85%)

Hormone health demand is rising, but many doctors aren’t trained for it

“Your bloodwork is fine” doesn’t always match how patients feel

High-cost concierge protocols create a massive gap in access

Microdosing GLP-1s is growing and isn’t only about losing weight

Blood work is the entry point to personalized longevity care

Some telehealth is “set it and forget it”—but follow-up changes outcomes

Research peptide sites can be risky compared to compliant pharmacy partners

Telehealth adoption is early—and Matthew sees 10–20x growth ahead

Chapters

00:01 Matthew’s 20-Year Growth Background (Digital Marketing + Customer Journey)

01:09 First Entry Into Telehealth (2015) and the “Lightbulb Moment”

02:20 Why He Went All-In and Acquired a Telehealth Platform

03:05 The GLP-1 Wave and Why the Industry Hasn’t “Evolved” Much

03:23 MyStart Growth: 13,000 Patients + What It Took to Get There

03:42 Early Startup Reality: Getting “Kicked” Until the Model Clicked

04:31 Why MyStart Became a Women-First Audience (85% Women, Mostly 50+)

05:56 HRT + Women’s Health: The Generational Impact of Past Medical Guidance

07:34 “Sorry, There’s Nothing We Can Do” — Mom’s Menopause Experience

08:04 Postpartum Reality: “Do I Get My Brain Back?” and the System Gap

09:24 The $6K–$8K Protocol Problem and Why Access Is Limited

10:34 Access + Affordability: $1,000–$1,400 vs $200–$300 per Month

12:10 GLP-1s Beyond BMI: Mental Health, Prevention, and Emerging Benefits

13:09 Microdosing GLP-1s: What People Miss (and Matthew’s Experience)

14:44 Blood Work + Longevity: Personalization as the Next Layer

16:30 Doctors Who “Check the Box” vs Doctors Who Actually Personalize Care

19:12 The Wild West: Research Peptides, Compliance, and Pharmacy Standards

22:19 Where Telehealth Is Heading in 2–5 Years (Cost Curves + New Meds)

25:12 Learning From Competitors: Pricing Models + Personalization Systems

26:35 The Question for the Next Guest: What Would You Change in Telehealth?